Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (4): 598-603    DOI: 10.31083/j.ejgo.2020.04.5247
Original Research Previous articles | Next articles
Lapatinib promotes ovarian cancer cell apoptosis through mROS-HtrA2/Omi pathways
Yuqing Yang1, , Huimin Zhang2, , Weiming Chen3, Xiaoyue Chen3, Xiaolin Yu4, *()
1Queen Mary Medical College, Nanchang University, Nanchang, P. R. China
2Department of Gynecology, Guizhou Provincial People's Hospital, Guiyang, P. R. China
3College of Medicine, Guizhou University, Guiyang, P. R. China
4Department of Gynecology and Obstetrics, First People's Hospital Affiliated to Nanchang University, Nanchang, P. R. China
Download:  PDF(572KB)  ( 242 ) Full text   ( 5 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Mitochondria play a pivotal role in regulating the viability of cancer cells. The role of lapatinib in cancer is poorly understood. This study investigated the downstream response to mitochondrial fragmentation using lapatinib to activate mitochondria. In this study cell viability was measured by MTT and LDH leakage assays. Apoptosis was determined by enzyme-linked immunosorbent assay (ELISA) and Annexin V/PI staining. Mitochondrial fragmentation was measured by qPCR and protein expression was detected by Western blot. Results showed that lapatinib increased ovarian cancer cell apoptosis in SKOV-3 cells via triggering mitochondrial fragmentation. Subsequently, mitochondrial fragmentation increased ROS production and facilitated HtrA2/Omi liberation from the mitochondria into the cytoplasm which inturn activated caspase-dependent cell apoptosis. The present results identified the mROS-HtrA2/Omi axis as a novel signaling pathway that is activated by mitochondrial fragmentation and promotes ovarian cancer cell apoptosis with lapatinib treatment.
Key words:  Ovarian carcinoma      Lapatinib      Mitochondria      mROS-HtrA2/Omi     
Submitted:  17 April 2019      Accepted:  26 August 2019      Published:  15 August 2020     
*Corresponding Author(s):  XIAOLIN YU     E-mail:  xiaolinyu09@aliyun.com
About author:  Contributed equally

Cite this article: 

Yuqing Yang, Huimin Zhang, Weiming Chen, Xiaoyue Chen, Xiaolin Yu. Lapatinib promotes ovarian cancer cell apoptosis through mROS-HtrA2/Omi pathways. European Journal of Gynaecological Oncology, 2020, 41(4): 598-603.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.04.5247     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I4/598

[1] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[2] S. Kalogeropoulos, E. Chronopoulou, E. Kourea, A. Siampalis, A. Kaponis, G.O Decavalas. Small cell ovarian carcinoma hypercalcemic type and endometrial adenocarcinoma in a 49-year-old patient: a very rare case[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1064-1066.
[3] S. Cierniak, R. Koktysz, M. Jesiotr, A. Gąsowska-Bodnar, L. Bodnar. Expression of the PI3K/AKT/mTOR pathway as a prognostic factor in patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 744-751.
[4] T. Hanikezi, W. Shaadaiti, A. Mayinuer, J.D. Zhao, M. Guzainuer, A. Mourboul, A. Zufeiya. Impacts of isoliquiritigenin on proliferation and apoptosis of human cervical cancer cells[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 425-430.
[5] C.E.S. Hoogstins, L.S.F. Boogerd, K.N. Gaarenstroom, C.D. de Kroon, J.J. Beltman, J.B.M.Z. Trimbos, T. Bosse, J. Vuyk, P.S. Low, J. Burggraaf, A.L. Vahrmeijer. Feasibility of folate receptor-targeted intraoperative fluorescence imaging during staging procedures for early ovarian cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 203-208.
[6] Xin Yan, Yu-Nong Gao, Quan Bao, Na An, Min Gao, Hong Zheng. Hepatic resection for recurrent metastatic ovarian carcinoma or peritoneal carcinoma: a retrospective case-control study[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 113-118.
[7] Ka Yu Tse, Philip Pun Ching Ip, Suk Kwan Lau, Tong Yow Ng, Kar Fai Tam, Annie Nga Yin Cheung, Hextan Yuen Sheung Ngan. Poor prognosis associated with venous thromboembolism in Asian patients with ovarian clear cell carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 903-910.
[8] F. Lai-Tiong. Long survival metastatic ovarian neoplasm under bevacizumab maintenance strategy[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 1015-1016.
[9] S. Pantovic, A. Stefanovic, J. Dotlic, S. Kadija, K. Jeremic, I. Likic, S. Repac, J. Stojnic, Z. Vilendecic, I. Pilic. Ovarian carcinoma diagnostic challenge: large ovarian carcinoma giving umbilical subcutaneous metastases without infiltrating intestines[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 813-816.
[10] Ling Wang, Xiao-tong Wu, Bo-wei Wang, Qiang Wang, Li-ying Han. miR-145 regulates proliferation and chemotherapy sensitivity of ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 634-640.
[11] W. MacNab, R.M. Glasspool, S. Shanbhag, A.H. Sadozye, K.A. Burton, I.A. McNeish, N.S. Reed, N. Siddiqui, M.K. Mehasseb. Outcomes of women not receiving treatment for advanced ovarian cancer in the West of Scotland: a retrospective analysis[J]. European Journal of Gynaecological Oncology, 2018, 39(1): 58-62.
[12] H.Y. Xu, Y. Wang, H. Zhang, J. Xu. The long non-coding RNA UCA1, as a prognostic biomarker for high grade serous ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 883-889.
[13] S. Kabukcuoglu. Calretinin expression in endometriosis. Is calretinin positive tubal epithelium origin of fallopian tube carcinoma?[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 905-909.
[14] M.R. Brincat, Y. Muscat Baron, E. Borg. Omentectomy in endometrial cancer: an evidence-based insight[J]. European Journal of Gynaecological Oncology, 2017, 38(4): 511-515.
[15] Y. Xiong, Y.Y. Xiong, Z.G. Xu, H.B. Cai. Differential expression of lysophosphatidic acid (LPA) receptors in human ovarian carcinomas[J]. European Journal of Gynaecological Oncology, 2017, 38(4): 564-569.
No Suggested Reading articles found!